Protalix Biotherapeutics’ (PLX) Buy Rating Reaffirmed at HC Wainwright
“Valuation methodology, risks and uncertainties. Our model yields an rNPV of $213M for PRX-102 using a 15% discount rate and 75% probability of approval, accounting for the Chiesi partnership and receipt of royalties on PRX-102 sales globally. We also ascribe an rNPV of $200M to alidornase alfa, a $100M rNPV for $50M rNPV for OPRX-106, translating into a price per share of $4.00. This assumes 148M shares outstanding as of end-2Q 2019.”,” the firm’s analyst wrote.
Separately, Zacks Investment Research raised Protalix Biotherapeutics from a hold rating to a buy rating and set a $0.50 price objective for the company in a research note on Tuesday, July 31st.
Protalix Biotherapeutics (NYSEAMERICAN:PLX) last released its quarterly earnings data on Thursday, August 9th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.03). The firm had revenue of $2.01 million during the quarter, compared to the consensus estimate of $7.00 million.
Several institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its stake in shares of Protalix Biotherapeutics by 13.2% in the second quarter. Renaissance Technologies LLC now owns 2,614,700 shares of the company’s stock valued at $1,124,000 after buying an additional 305,200 shares during the period. Opaleye Management Inc. increased its stake in shares of Protalix Biotherapeutics by 78.6% in the first quarter. Opaleye Management Inc. now owns 3,260,000 shares of the company’s stock valued at $1,760,000 after buying an additional 1,435,000 shares during the period. Finally, SG Americas Securities LLC acquired a new position in shares of Protalix Biotherapeutics in the first quarter valued at approximately $121,000.
About Protalix Biotherapeutics
Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.
Further Reading: Stock Symbols Definition, Examples, Lookup
Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.